Insulin is a key anabolic hormone that plays a crucial role in growth, differentiation and metabolism. Insulin action is initiated by the binding of the hormone to its tyrosine kinase cell surface receptor, leading to the multisite autophosphorylation of the receptor. This results in the activation of the receptor kinase and subsequent tyrosine phosphorylation of insulin receptor substrates, most of which are docking proteins for signaling molecules. For the last several years, our laboratory has been interested in the mechanisms that lead to the modulation of insulin signal transduction, and hence might be involved in insulin resistance found in obesity and type II diabetes. For this review, we have focused on three 'modulators' of insulin action: hyperinsulinemia, suppressor of cytokine signaling proteins and advanced glycation end products.
Introduction
Type II diabetes is a polygenic disease resulting from a complex interplay between genetic status and environmental conditions. At the onset of disease progression, the major peripheral insulin-responsive tissues, such as muscle and adipose tissue, display a diminished response to insulin, resulting in a decreased disposal of excess circulating glucose. At the same time, the insulin-inhibitory effect on hepatic gluconeogenesis becomes less pronounced. To maintain normoglycemia, an increased amount of insulin is released by the pancreatic beta cells, resulting in hyperinsulinemia. At this stage, the intracellular insulinsignaling machinery is deregulated by a number of as yet poorly understood events, likely to include a decrease of insulin receptor substrates (IRS) and the induction of expression of suppressor of cytokine signaling (SOCS) proteins.
In the long term, increased insulin secretion impinges on beta-cell function, and the resulting hyperinsulinemia exacerbates the insulin-resistant state of the peripheral tissues, leading eventually to overt diabetes. Under hyperglycemic conditions, the nonenzymatic linking of glucose to proteins augments, generating superphysiological levels of advanced glycation end products (AGEs), further contributing to the disease progression.
The diversity of the etiology of diabetes, in combination with the intricacies of unraveling the cause of the disease, has hindered progress towards a comprehensive understanding of the exact role of insulin signal modulators in the development of insulin resistance in obesity and type II diabetes. We will summarize here recent research performed in our laboratory that addresses the contribution of hyperglycemia, insulin (or cytokine)-induced expression of SOCS proteins and AGEs towards the progression of insulin resistance and eventually diabetes.
Hyperinsulinemia
Impaired glucose tolerance precedes type II diabetes and is characterized by hyperinsulinemia, which develops to counterbalance peripheral hormonal resistance. To unravel the pernicious actions of hyperinsulinemia on skeletal muscle, we analyzed the effect of hyperinsulinemia upon the intracellular insulin signaling network, and the means by which this modifies the physiological insulin-responsive status in L6 muscle cells. L6 muscle cells were chronically exposed to insulin and subsequently stimulated by a second, acute insulin treatment. We found that prolonged exposure to insulin induced a cellular insulin-resistant state, characterized by a marked desensitization of the insulin-induced phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB) and mitogen-activated protein kinase (MAPK) pathways, eventually leading to a diminished glucose uptake following a second acute stimulation. 1 The diminished insulin responsiveness was independent of alterations in the function of the insulin receptor; rather, it correlated with a decrease in the protein levels of the insulin receptor substrates 1 and 2 (IRS-1 and -2). Since decreased levels of IRS proteins have been reported in insulin-resistant subjects as well as diabetic patients, such decreases might be causally linked to disease progression. 2 Several recent studies, mainly focusing on the IRS-1 isoform, have addressed the molecular mechanism whereby IRS proteins are degraded. The currently accepted view is that the IRS degradation pathway is primed by phosphorylation on IRS protein serine residues and accomplished by the proteasome degradative pathway. Interestingly, serine phosphorylation of IRS proteins is also known to attenuate insulin action, regardless of the degradative step.
Which are, then, the serine kinases phosphorylating IRS proteins? A general feature is that IRS serine phosphorylation is blocked by the PI3K inhibitors wortmannin or LY294002. Thus, several kinases downstream of PI3K have been proposed as IRS serine kinases, including glycogen synthase kinase 3 (GSK-3), mammalian target of rapamycin (mTOR) and the atypical protein kinase C (PKCz) (for a review see Zick 3 ). Adenosine 5 0 -monophosphate-activated protein kinase (AMPK) has also been shown to phosphorylate IRS-1; 4 however, serine phosphorylation of IRS-1 mediated by this kinase appeared to ameliorate, rather than suppress, the IRS-1 action in response to insulin. In keeping with this, it has been recently demonstrated that a threshold serine-phosphorylation level is necessary for IRS protein function.
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PI3K is the major enzyme mediating insulin's metabolic action via production of 3 0 -phosphorylated phosphoinositides, and at the same time acting as a feedback relay by governing IRS serine phosphorylation by downstream kinases. In addition to its lipid kinase activity, PI3K has been shown also to possess an intrinsic protein serine kinase activity, and coimmunoprecipitation studies revealed that IRS-1 is a PI3K protein substrate. 6 We thus evaluated whether PI3K could phosphorylate IRS-1, contributing to its desensitization and degradation in L6 muscle cells. 32 P orthophosphate labeling experiments revealed that the IRS-1 maximal phosphorylation on serine/threonine residues observed following prolonged exposure to insulin was reduced by more than 90% after the inhibition of PI3K, but significantly less by the inhibition of either mTOR or MAPK. Likewise, IRS-1 degradation was fully abolished by PI3 K inhibition, but not by inhibition of MAPK, mTOR or any PKC isoform. These data indicated that PI3K itself or at most a mTOR or PKC upstream kinase (namely 3-phosphoinositide-dependent kinase-1 (PDK) or PKB) controls the IRS-1 phosphorylation events relevant to drive IRS-1 degradation. Taking advantage of the newly identified PDK inhibitor TPCK, 7 we have demonstrated that insulin-induced IRS-1 degradation is not impaired by PDK inhibition, strongly suggesting that IRS-1 serine phosphorylation mediated by PI3K provides the essential step towards the degradative pathway. 1 Currently, we are investigating whether similar degradative mechanisms are used to downregulate IRS-2, and, by employing PI3K mutants that solely retain a protein kinase activity, 8 we are detailing the precise molecular mechanism linking serine phosphorylation to proteasomal degradation.
SOCS proteins
The SOCS proteins form a growing family of proteins first described for their ability to regulate cytokine signaling negatively. The evidence from our laboratory, along with others, has shown that the SOCS proteins are also involved in a negative feedback loop regulating insulin signaling. The archetypal member of the SOCS family of proteins is cytokine-inducible src-homology 2 (SH2) protein (CIS), cloned originally as an immediate-early cytokine-responsive gene. 9 A clearer picture of the importance of these molecules came with the identification of three genes, SOCS-1 to -3, cloned via their ability to inhibit the macrophage differentiation of M1 cells in response to interleukin-6 and subsequently described as negative regulators of cytokine signaling. 10 The family is currently composed of eight members, CIS and SOCS-1 through -7. These proteins have similar structural characteristics including a unique NH2-terminal domain of variable length, a central SH2 domain and a COOH-terminal 'SOCS box', with this structural resemblance reflecting their functional similarities. The SOCS proteins act as part of classical negative feedback circuits, acting via three identified mechanisms. First, they bind and inactivate Janus kinases (JAKs). They can also impede access of other crucial signal transduction mediators such as signal transducer and activators of transcription (STATs) and SHP2 to receptor binding sites. More recent evidence suggests that the 'SOCS box' acts as an adaptor to facilitate the ubiquitination of signaling proteins and their subsequent targeting to the proteasome. However, the precise mechanisms of action vary between the different proteins. Studies in our laboratory have focused primarily on the role of the SOCS-3 protein, having demonstrated that it plays a role in the negative feedback regulation of the insulin signaling machinery. Both SOCS-1 and SOCS-6 have also been implicated in the regulation of insulin signaling. 11 Initial experiments showed that SOCS-3 expression is induced by insulin in insulin-sensitive cell lines, such as 3T3-L1 adipocytes, and in tissues of insulin-treated mice, such as adipose tissue, liver and muscle. This induction of SOCS-3 expression is STAT dependent, as cells lacking STAT5B and insulin receptor mutants incapable of STAT5B activation are unable to induce SOCS-3.
12,13 Furthermore, evidence suggests that the induced SOCS-3 proteins may compete with insulin receptor substrates such as IRS, STAT5
Modulators of insulin action L Pirola et al and SHC, as SOCS-3 binds via its SH2 domain to the same docking site (tyrosine960) of the insulin receptor. The demonstrated involvement in the physical interactions of the insulin signaling pathway is functionally reflected by a SOCS-mediated decrease in insulin-induced p85 association with IRS-1, decreased PI3K activation and reduced activation of PKB, MAPK and STAT5. 11, 12, 13, 14 In theory, a SOCS protein would be capable of mediating these effects at different levels; by introducing competition for crucial receptor binding sites (a decrease in IRS phosphorylation resulting from competition with IRS-1 for the phosphoY960 binding site has been demonstrated 14 )
; by an inhibition of JAK, 15 or by the SOCS-mediated ubiquitinmediated degradation of IRS. 16 Which of these mechanisms contribute to a negative regulation of the pathway in a physiological state, to what extent, and the identity of the SOCS proteins that play the major role remains to be established and may well depend, at least in part, on the level of SOCS expression. In some cases, there appears to be specificity with respect to the SOCS protein involved in inhibition. For example, SOCS-3 but not SOCS-2 or CIS inhibits signaling by leptin, a hormone that regulates food intake. 17 Interestingly, this is, in turn, linked with a pathophysiological condition, with the demonstration of increased levels of SOCS-3 mRNA present in the hypothalamus of leptin-resistant obese mice. Similarly, the SOCS proteins have been implicated in insulin resistance in animal models. SOCS-1 À/À mice are hypoglycemic despite levels of circulating insulin as in wildtype mice, while SOCS-1 overexpression via adenoviral injection leads to fasting hyperglycemia and glucose intolerance. 15 Work in our laboratory has shown that SOCS-3 is overexpressed in the adipose tissue of obese mice. In addition, in the adipose tissue of mice made insulin resistant by tumor necrosis factor-alpha (TNF-alpha) injection, an induction of SOCS-3 expression is observed, while its expression is strikingly reduced in the adipose tissue of ob/ ob mice lacking TNF-alpha receptors. 14 Taking these findings together, it appears that SOCS3 acts as a negative regulator of the intracellular network of insulin action, a role that may have considerable physiological consequences in the context of insulin resistance and progression to type II diabetes.
Glycated proteins
Hyperglycemia per se contributes to insulin resistance through ensuing glucotoxic effects acting upon the pancreatic beta cell. 18 In addition, higher circulating glucose leads to the nonenzymatic formation of AGEs that themselves have negative consequences and are implicated in the pathogenesis of diabetic complications, such as diabetic retinopathy.
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To investigate the effects of AGEs on peripheral insulinresponsive tissues, we focused on an L6 myotube system. L6 cells pre-exposed to AGEs showed decreased responsiveness of the metabolic PI3K/PKB branch of the intracellular insulin signaling machinery. 20 AGE pretreatment thus decreased insulin-stimulated IRS-1 and -2 tyrosine phosphorylation and associated PI3K activity, PKB and GSK-3 activation and ultimately end point metabolic responses such as glucose uptake and glycogen synthesis, without affecting signaling through the mitogenic MAPK branch. The inhibitory action of AGEs on insulin signaling was found to be mediated by PKC-alpha, most likely by serine phosphorylation on IRS proteins, leading to a selective attenuation of the PI3K/PKB, but not of the MAPK signaling cascade. The aim now is to define the mechanism of signal transduction between the AGE receptor and PKC-alpha.
Summary and conclusions
Both genetic defects/predispositions and environmental factors are likely to contribute to the complex interplay, which results in insulin resistance and leads to type II diabetes. Considering the large series of molecules involved in the intracellular network of insulin signaling, it is likely that even small defects in key molecules occurring concurrently will lead to insulin resistance and type II diabetes.
With the further unraveling of the insulin signaling pathways, it will be possible to localize these defects precisely and hopefully to correct them. Our laboratory is currently addressing how deregulations in insulin signaling machinery can lead to the development of insulin resistance and type II diabetes. We have focused on 'modulators' of insulin action that affect insulin signaling at different levels; extracellularly (AGEs), intracellularly (effects of hyperinsulinemia on insulin signaling) and at the level of gene transcription (SOCS proteins). While diverse molecular effects are assigned to each of these modulators, it is of interest to note that they all converge to a certain extent on IRS proteins, leading to a downregulation of their action through competition, or by increasing their serine phosphorylation state and promoting degradation. Further investigation of these proteins and their diverse actions in both physiological as well as insulin-resistant states should lead us to a better understanding of the complexities of insulin resistance and type II diabetes.
